Search Results

You are looking at 11 - 20 of 497 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Natasha C. Townsend, Karen Ruth, Tahseen Al-Saleem, Eric M. Horwitz, Mark Sobczak, Robert G. Uzzo, Rosalia Viterbo, and Mark K. Buyyounouski

have been made regarding the need for a second confirmatory pathology review (SPR) before beginning treatment. Furthermore, no reported series have examined the impact of an SPR for men receiving external-beam radiotherapy. Of the 2 series that examine

Full access

Anisley Valenciaga, O. Hans Iwenofu, and Gabriel Tinoco

elective robotic hysterectomy and bilateral salpingo-oophorectomy 2 weeks later. Final pathology from the surgery revealed PLU with an anterior and posterior size of 7.0 × 6.0 × 2.1 cm and 8.0 × 6.5 × 4.0 cm, respectively. The histopathology was high

Full access

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andrea Trotti III, Randal S. Weber, Gregory Wolf, and Frank Worden

Full access

Elizabeth R. Plimack and Gary R. Hudes

Advanced renal cell carcinoma (RCC) is a heterogeneous disease with variable histology, biology, and response to treatment. In the past 5 years, 6 new agents have been approved for the treatment of RCC, and many more are in clinical development. With an ever-increasing number of treatment options, selecting among them for a particular patient can be a daunting task for clinicians. This article describes how treatment choice can be guided by the disease setting and histology, as well as patient characteristics, comorbidities, and preference within the context of available data. Results from clinical trials are combined with practical considerations to make recommendations for first-line and subsequent treatment of patients with clear cell and non-clear cell RCC. These recommendations should supplement the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of advanced RCC.

Full access

Harry W. Herr

pathology versus (B) repeat TUR pathology. Abbreviations: CIS, carcinoma in situ; HG, high grade; LG, low grade; TUR, transurethral resection. and improved staging accuracy. Incomplete resection is responsible for most early recurrences, providing a

Full access

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

Full access

Denise Leung, Xiaosi Han, Tom Mikkelsen, and L. Burt Nabors

pathology detection, and display most lesions, including tumors and edema, with higher signal intensity than T2 images. However, the tumor focus in FLAIR or T2 images is not well separated from surrounding edema, gliosis, or ischemic changes. T1-weighted

Full access

Ahmad Hamad, Aatur D. Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J. Zeh, and Amer H. Zureikat

is located on chromosome 17q21 and acts as a proto-oncogene. It is a cell membrane receptor tyrosine kinase that is activated following ligand binding and receptor dimerization. 8 Dimerization Figure 4. Microscopic pathology image of patient

Full access

Edward E. Partridge, Nadeem Abu-Rustum, Anna Giuliano, Stewart Massad, Joan McClure, Mary Dwyer, and Miranda Hughes

guidelines from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology, the NCCN Guidelines for Cervical Cancer Screening were discontinued. 1 , 17 Development of the screening

Full access

Christopher K. Bichakjian, Thomas Olencki, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Clifford S. Perlis, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Andrew E. Werchniak, Sandra L. Wong, John A. Zic, Karin G. Hoffmann, Nicole R. McMillian, and Maria Ho

.2014 Version 1.2014, 12-20-13 ©2014 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Pathology Report The